Your browser doesn't support javascript.
loading
Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma.
Jang, Jeong Won; Choi, Jong Young; Bae, Si Hyun; Kim, Chang Wook; Yoon, Seung Kew; Cho, Se Hyun; Yang, Jin Mo; Ahn, Byung Min; Lee, Chang Don; Lee, Young Sok; Chung, Kyu Won; Sun, Hee Sik.
Afiliación
  • Jang JW; Division of Hepatology, Department of Internal Medicine, College of Medicine, WHO collaborating Center on Viral Hepatitis, Catholic University of Korea, #505 Banpodong, Seocho-ku, 137-040 Seoul, South Korea.
J Hepatol ; 41(3): 427-35, 2004 Sep.
Article en En | MEDLINE | ID: mdl-15336446
BACKGROUND/AIMS: Reactivation of hepatitis B virus (HBV) replication is a well-known complication in cancer patients receiving chemotherapy. The aims of this study were to determine the incidence of HBV reactivation in hepatocellular carcinoma (HCC) patients undergoing transarterial chemo-lipiodolization, and to clarify factors contributing to HBV reactivation. METHODS: From April 2001 to September 2002, 146 HBsAg positive patients newly diagnosed as HCC were enrolled in the study. Among these, 83 patients underwent transarterial chemo-lipiodolization using epirubicin and/or cisplatin, and 63 received other treatments. RESULTS: In total, HBV reactivation occurred in 30 (20.5%) patients (28 with chemo-lipiodolization and 2 with other treatments), and of the 30 patients, 19 (13.0%) (18 with chemo-lipiodolization and 1 with other treatments) developed hepatitis. Chemo-lipiodolization was significantly correlated with a higher incidence of hepatitis attributed to HBV reactivation than other treatments (21.7% vs. 1.6%, P<0.001), irrespective of HBeAg or HBV DNA. Among 83 patients undergoing chemo-lipiodolization, HBV reactivation occurred in 28 (33.7%) patients, and HBeAg seropositivity was the only independent predictor of HBV reactivation (P=0.013). Three (10.7%) of them died of hepatic decompensation resulting from HBV reactivation. CONCLUSIONS: Transarterial chemo-lipiodolization can reactivate HBV, and HBeAg-positive HCC patients receiving chemo-lipiodolization should be closely monitored for HBV reactivation.
Asunto(s)
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quimioembolización Terapéutica / Carcinoma Hepatocelular / Hepatitis B Crónica / Neoplasias Hepáticas Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2004 Tipo del documento: Article País de afiliación: Corea del Sur Pais de publicación: Países Bajos
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quimioembolización Terapéutica / Carcinoma Hepatocelular / Hepatitis B Crónica / Neoplasias Hepáticas Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2004 Tipo del documento: Article País de afiliación: Corea del Sur Pais de publicación: Países Bajos